Image pharmaphorum Editor News Ensuring safety by digitally linking prescription management... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care. News Sanofi in final stages of negotiation in sale of generics ar... Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. Views & Analysis LHON diagnosis: Opening peoples’ eyes to the invisible suffe... Maryse Roger has firsthand experience of Leber’s hereditary optic neuropathy (LHON), having first assisted her two brothers as their sight deteriorated and then leading the care of her son News NHS ‘worse than average’ in treating common causes of death A report by four think tanks has concluded that the NHS is failing when it comes to treating eight of the 12 most common causes of death. Load more results
News Ensuring safety by digitally linking prescription management... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
News Sanofi in final stages of negotiation in sale of generics ar... Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International.
Views & Analysis LHON diagnosis: Opening peoples’ eyes to the invisible suffe... Maryse Roger has firsthand experience of Leber’s hereditary optic neuropathy (LHON), having first assisted her two brothers as their sight deteriorated and then leading the care of her son
News NHS ‘worse than average’ in treating common causes of death A report by four think tanks has concluded that the NHS is failing when it comes to treating eight of the 12 most common causes of death.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
